Detalhe da pesquisa
1.
PD-1-cis IL-2R agonism yields better effectors from stem-like CD8+ T cells.
Nature
; 610(7930): 161-172, 2022 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-36171284
2.
CD19-CD28: An affinity-optimized CD28 agonist for combination with glofitamab (CD20-TCB) as off-the-shelf immunotherapy.
Blood
; 2024 Mar 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-38437725
3.
ROCKETS - a novel one-for-all toolbox for light sheet microscopy in drug discovery.
Front Immunol
; 14: 1034032, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-36845124
4.
Rapamycin-sensitive signals control TCR/CD28-driven Ifng, Il4 and Foxp3 transcription and promoter region methylation.
Eur J Immunol
; 41(7): 2086-96, 2011 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-21480212
5.
A Novel EGFRvIII T-Cell Bispecific Antibody for the Treatment of Glioblastoma.
Mol Cancer Ther
; 21(10): 1499-1509, 2022 10 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-35915983
6.
IL-7 adjuvant treatment enhances long-term tumor-antigen-specific CD8+ T-cell responses after immunization with recombinant lentivector.
Blood
; 113(26): 6629-37, 2009 Jun 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-19383968
7.
International Consensus on Minimum Preclinical Testing Requirements for the Development of Innovative Therapies For Children and Adolescents with Cancer.
Mol Cancer Ther
; 20(8): 1462-1468, 2021 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-34108262
8.
Multi-Parameter Quantitative Imaging of Tumor Microenvironments Reveals Perivascular Immune Niches Associated With Anti-Tumor Immunity.
Front Immunol
; 12: 726492, 2021.
Artigo
em Inglês
| MEDLINE | ID: mdl-34421928
9.
Cross-linking of T cell to B cell lymphoma by the T cell bispecific antibody CD20-TCB induces IFNγ/CXCL10-dependent peripheral T cell recruitment in humanized murine model.
PLoS One
; 16(1): e0241091, 2021.
Artigo
em Inglês
| MEDLINE | ID: mdl-33406104
10.
Corrigendum: Combination of T-Cell Bispecific Antibodies With PD-L1 Checkpoint Inhibition Elicits Superior Anti-Tumor Activity.
Front Oncol
; 11: 650149, 2021.
Artigo
em Inglês
| MEDLINE | ID: mdl-33614518
11.
Simlukafusp alfa (FAP-IL2v) immunocytokine is a versatile combination partner for cancer immunotherapy.
MAbs
; 13(1): 1913791, 2021.
Artigo
em Inglês
| MEDLINE | ID: mdl-33974508
12.
Combination of T-Cell Bispecific Antibodies With PD-L1 Checkpoint Inhibition Elicits Superior Anti-Tumor Activity.
Front Oncol
; 10: 575737, 2020.
Artigo
em Inglês
| MEDLINE | ID: mdl-33330050
13.
Dendritic cells dictate responses to PD-L1 blockade cancer immunotherapy.
Sci Transl Med
; 12(534)2020 03 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-32161104
14.
Extracellular HMGB1, a signal of tissue damage, induces mesoangioblast migration and proliferation.
J Cell Biol
; 164(3): 441-9, 2004 Feb 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-14744997
15.
Combining venetoclax and azacytidine with T-cell bispecific antibodies for treatment of acute myeloid leukemia: a preclinical assessment.
Leukemia
; 38(2): 398-402, 2024 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-38212534
16.
Efficient induction of tumor antigen-specific CD8+ memory T cells by recombinant lentivectors.
Cancer Res
; 66(2): 1155-60, 2006 Jan 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-16424053
17.
CD20-TCB with Obinutuzumab Pretreatment as Next-Generation Treatment of Hematologic Malignancies.
Clin Cancer Res
; 24(19): 4785-4797, 2018 10 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-29716920
18.
Promises and limitations of murine models in the development of anticancer T-cell vaccines.
Int Rev Immunol
; 25(5-6): 269-95, 2006.
Artigo
em Inglês
| MEDLINE | ID: mdl-17169777
19.
Application of a MABEL Approach for a T-Cell-Bispecific Monoclonal Antibody: CEA TCB.
J Immunother
; 39(7): 279-89, 2016 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-27404941
20.
In Vivo Fluorescence Imaging of the Activity of CEA TCB, a Novel T-Cell Bispecific Antibody, Reveals Highly Specific Tumor Targeting and Fast Induction of T-Cell-Mediated Tumor Killing.
Clin Cancer Res
; 22(17): 4417-27, 2016 Sep 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-27117182